Regulatory Action to Protect Access to Hydroxychloroquine for Approved Rheumatic Indications During COVID-19 in New Zealand.

Duffy, Eamon; Arroll, Nicola; Beasley, Richard; Hills, Thomas

Duffy, Eamon; Arroll, Nicola; Beasley, Richard; Hills, Thomas.

Duffy E; Auckland District Health Board, Auckland, New Zealand.
Arroll N; Auckland District Health Board, Auckland, New Zealand.
Beasley R; Medical Research Institute of New Zealand and Capital and Coast District Health Board, Wellington, New Zealand.
Hills T; Auckland District Health Board Auckland, New Zealand and Medical Research Institute of New Zealand, Wellington, New Zealand.

Arthritis Rheumatol ; 73(5): 896-897, 2021 05.

Article in English | MEDLINE | ID: covidwho-1121982

Subject(s)

Antirheumatic Agents/supply & distribution; Antirheumatic Agents/therapeutic use; COVID-19 Drug Treatment; Drug and Narcotic Control; Health Services Accessibility; Hydroxychloroquine/supply & distribution; Hydroxychloroquine/therapeutic use; Rheumatic Diseases/drug therapy; Evidence-Based Medicine; Humans; New Zealand; Off-Label Use; Practice Patterns, Physicians'; SARS-CoV-2; United States

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Rheumatic Diseases / Antirheumatic Agents / Drug and Narcotic Control / COVID-19 Drug Treatment / Health Services Accessibility / Hydroxychloroquine Type of study: Prognostic study Limits: Humans Country/Region as subject: North America / Oceania Language: English Journal: Arthritis Rheumatol Year: 2021 Document Type: Article Affiliation country: Art.41643

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google